Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 34031-32-8 Chemical Structure| 34031-32-8

Structure of Auranofin
CAS No.: 34031-32-8

Chemical Structure| 34031-32-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Auranofin (SKF-39162) functions as a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.2 μM and demonstrates antiviral activity against SARS-CoV21, with a CC50 of 4.2 μM for monkey kidney Vero E6 cells.

Synonyms: SKF-39162; NSC 321521; NSC 321521, Ridauragold thiol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Auranofin

CAS No. :34031-32-8
Formula : C20H34AuO9PS
M.W : 678.48
SMILES Code : O(C(C)=O)[C@@H]1[C@@H](OC(C)=O)[C@H]([S-][Au+][P](CC)(CC)CC)O[C@H](COC(C)=O)[C@H]1OC(C)=O
Synonyms :
SKF-39162; NSC 321521; NSC 321521, Ridauragold thiol
MDL No. :MFCD00080759
InChI Key :AUJRCFUBUPVWSZ-UHFFFAOYSA-M
Pubchem ID :24199313

Safety of Auranofin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H318-H334-H350-H360
Precautionary Statements:P261-P280-P301+P310-P305+P351+P338-P342+P311
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 0.1 µM 1 hour To evaluate the effect of aurocyanide on NLRP3 inflammasome activity, the results showed that aurocyanide significantly inhibited NLRP3 inflammasome activity Arch Pharm Res. 2023 Mar;46(3):149-159.
LX-2 cells 0.01–1 µM 2 days To evaluate the effect of aurocyanide on the proliferation of LX-2 cells, the results showed that aurocyanide significantly suppressed the proliferation of LX-2 cells Arch Pharm Res. 2023 Mar;46(3):149-159.
MDA-MB 435 S cells 4~5 µM 24 hours AF induces paraptosis in breast cancer cells, a non-apoptotic cell death mode characterized by dilation of the endoplasmic reticulum (ER) and mitochondria. Cell Death Dis. 2023 Jan 19;14(1):42.
MDA-MB 231 cells 4~5 µM 24 hours AF induces paraptosis in breast cancer cells, a non-apoptotic cell death mode characterized by dilation of the endoplasmic reticulum (ER) and mitochondria. Cell Death Dis. 2023 Jan 19;14(1):42.
BT549 cells 4~5 µM 24 hours AF induces paraptosis in breast cancer cells, a non-apoptotic cell death mode characterized by dilation of the endoplasmic reticulum (ER) and mitochondria. Cell Death Dis. 2023 Jan 19;14(1):42.
LX-2 cells 30 nM and 50 nM 24 hours To evaluate the effect of Auranofin on fibrosis in LX-2 cells, results showed that Auranofin reduced fibrosis markers and inhibited cell proliferation. Clin Mol Hepatol. 2022 Oct;28(4):827-840.
HepG2 cells 100 nM and 500 nM 24 hours To evaluate the effect of Auranofin on lipid accumulation in HepG2 cells, results showed that Auranofin reduced lipid accumulation and increased antioxidant markers. Clin Mol Hepatol. 2022 Oct;28(4):827-840.
293T cells 100 nM 3 hours To investigate the interaction of Auranofin with UBA1 and E2 ubiquitin-conjugating enzymes, enhancing UBA1 activity. Nat Commun. 2023 Aug 9;14(1):4798.
Fungal hyphae 8 or 16 μg/ml 4 hours Quantification of thioreductase activity and inhibition of fungal growth Virulence. 2021 Dec;12(1):1076-1090.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced obese mice Intraperitoneal injection 1 mg/kg Three times per week for one month Auranofin significantly improved insulin sensitivity, reduced serum leptin levels, and decreased hepatic fat accumulation in obese mice. Cell Metab. 2022 Dec 6;34(12):1932-1946.e7
C57BL/6N mice Bile duct ligation (BDL) model and Western diet-induced NASH model Oral 1 mg/kg, 3 mg/kg, 10 mg/kg 8 weeks To evaluate the effect of Auranofin on hepatic fibrosis and steatosis, results showed that Auranofin reduced hepatic fibrosis and lipid accumulation, and increased antioxidant markers. Clin Mol Hepatol. 2022 Oct;28(4):827-840.
BALB/c mice TAA-induced liver fibrosis model Oral 10 mg/kg 6 times a week for 8 weeks To evaluate the inhibitory effect of aurocyanide on TAA-induced liver fibrosis, the results showed that aurocyanide significantly reduced the fibrotic score and area Arch Pharm Res. 2023 Mar;46(3):149-159.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01557348 - Completed - -
NCT02770378 Glioblastoma Phase 1 Active, not recruiting March 2020 Germany ... More >> University of Ulm School of Medicine Ulm, Baden-Württemberg, Germany, 89081 Less <<
NCT01557348 - Completed - -
NCT02961829 Chronic Infection ... More >> HIV Less << Not Applicable Active, not recruiting March 2020 Brazil ... More >> CCDI Sao Paulo, SP, Brazil, 04040002 Less <<
NCT01737502 Extensive Stage Small Cell Lun... More >>g Carcinoma Lung Adenocarcinoma Recurrent Non-Small Cell Lung Carcinoma Recurrent Small Cell Lung Carcinoma Squamous Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer Less << Phase 1 Phase 2 Recruiting November 2018 United States, Arizona ... More >> Mayo Clinic in Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Referral Office    855-776-0015       Principal Investigator: Helen J. Ross Less <<
NCT02968927 Tuberculosis Phase 2 Recruiting December 2020 South Africa ... More >> The Aurum Institute: Tembisa Clinical Research Centre Recruiting Tembisa, Gauteng, South Africa, 1736 Less <<
NCT02063698 Pain Phase 2 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT02736968 Amoebic Dysentery ... More >> Giardiasis Less << Phase 2 Recruiting May 31, 2020 Bangladesh ... More >> International Center for Diarrheal Disease Research Bangladesh - Parasitology Recruiting Dhaka, Bangladesh, 1212 Less <<
NCT02089048 Amoebiasis PHASE1 COMPLETED 2015-05-13 Quintiles Phase I Services - O... More >>verland Park, Overland Park, Kansas, 66211-1553, United States Less <<
NCT01419691 Chronic Lymphocytic Leukemia (... More >>CLL) Small Lymphocytic Lymphoma Leukemia, Prolymphocytic Less << Phase 2 Completed - United States, Kansas ... More >> University of Kansas Cancer Center Westwood, Kansas, United States, 66205 Less <<
NCT02126527 Recurrent Non-small Cell Lung ... More >>Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Withdrawn(no participants enro... More >>lled) Less << - United States, Florida ... More >> Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 Less <<
NCT02176135 HIV PHASE1|PHASE2 WITHDRAWN 2025-01-17 University of Miami - AIDS Cli... More >>nical Research Unit, Miami, Florida, 33136, United States Less <<
NCT01747798 Recurrent Fallopian Tube Cance... More >>r Recurrent Ovarian Epithelial Cancer Recurrent Primary Peritoneal Cavity Cancer Less << Not Applicable Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT03456700 Ovarian Serous Tumor ... More >> Recurrent Ovarian Carcinoma Less << Phase 2 Recruiting March 15, 2023 United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clincial Trials Referral Office    855-776-0015       Principal Investigator: Aminah Jatoi Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.47mL

0.29mL

0.15mL

7.37mL

1.47mL

0.74mL

14.74mL

2.95mL

1.47mL

References

 

Historical Records

Categories